SCHEMBL1647381

SCHEMBL1647381

Cc1ccc(OCc2ccccc2)c(C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.67
L3MBTL1 Q9Y468 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
POLB P06746 1/20 0.60
LRRK2 Q5S007 2/20 0.59
MRGPRX4 Q96LA9 3/20 0.59
PTGER1 P34995 4/20 0.55
PTGER4 P35408 2/20 0.55
PTGER3 P43115 2/20 0.55
PTGER2 P43116 2/20 0.55
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MCL1 Q07820 1/20 0.53
FFAR4 Q5NUL3 1/20 0.52
CTSV O60911 1/20 0.52
CTSL P07711 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707535 0.89 MAPT (0.63) FOLH1L3MBTL1LRRK2MRGPRX4PTGER1
SCHEMBL6449105 0.89 MAPT (0.63) FOLH1L3MBTL1LRRK2MRGPRX4PTGER1
SCHEMBL28035504 0.88 LRRK2 (0.55) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL38657580 0.88 LRRK2 (0.57) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL21327456 0.88 LRRK2 (0.57) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL8168015 0.88 MCL1 (0.64) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL1646770 0.87 LRRK2 (0.56) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL5171831 0.87 MRGPRX4 (0.59) FOLH1LRRK2MRGPRX4PTGER1PTGER4
SCHEMBL11565369 0.87 LRRK2 (0.59) FOLH1L3MBTL1KDM4EALDH1A1POLB
SCHEMBL344398 0.84 FOLH1 (0.70) FOLH1L3MBTL1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116751200-A Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-09-15 CN disclosed
CN-110114071-B Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-07-04 CN disclosed
CN-105612158-A Antagonists of somatostatin receptor subtype 5 (sstr5) TAKEDA PHARMACEUTICALS CO 2016-05-25 CN disclosed
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 FOLH1 4250/4885L3MBTL1 1685/4885KDM4E 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.